Resources
8 Results (showing 1 - 8)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 10/12/2020 (updated 3/29/2024)
This report summarizes current (as of 2011) guidelines or recommendations published by multiple agencies of the U.S. Department of Health and Human Services (DHHS) for prevention and control of human immunodeficiency virus (HIV) infection, viral hepatitis, sexually transmitted diseases (STDs), and tuberculosis (TB) for persons who use drugs illicitly.
Posted 2/3/2021 (updated 4/4/2024)
The opioid epidemic is the result of a complex system of varied and interrelated factors. This webinar introduced a systems thinking approach and tools to address such complex public health challenges. The Georgia Health Policy Center’s Opioid Systems Map was presented as a case study for the creation and application of systems mapping in local communities. The webinar fostered a holistic view of the opioid epidemic and described opportunities to further develop systems thinking capacity for application to grantees’ local opioid response.
Posted 3/10/2021 (updated 4/5/2024)
The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic groups, including organized violent gangs, serve in domestic drug trafficking. The most widely trafficked drugs are discussed in terms of their availability, consumption and overdose related deaths, production and cultivation, transportation, and distribution.
Posted 2/16/2022 (updated 3/26/2024)
In the United States, combined stimulant/opioid overdose mortality has risen dramatically over the last decade. These increases may particularly affect non-Hispanic Black and Hispanic populations. We used death certificate data from the US National Center for Health Statistics (2007–2019) to compare state-level trends in overdose mortality due to opioids in combination with 1) cocaine and 2) methamphetamine and other stimulants (MOS) across racial/ethnic groups (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic Asian American/Pacific Islander).
Posted 3/16/2022 (updated 3/27/2024)
We are pleased to share that the Substance Abuse and Mental Health Services Administration (SAMHSA) has rolled out a new 988 website today – available at samhsa.gov/988. The 988 website is designed to serve as your one-stop-shop for 988 resources from SAMHSA.
Notably, we want to make sure you’re aware that the site contains a 988 partner toolkit. The partner toolkit is intended for SAMHSA’s 988 implementation partners (crisis call centers, state mental health programs, substance use treatment providers, behavioral health systems, and others) to provide key messages, FAQs, and more information about what 988 is and how it will work.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 11/1/2022 (updated 3/27/2024)
The webinar held by NASTAD on October 26, 2022, 4:00-5:30pm featured a dynamic discussion on integrating harm reduction principles and practices, including naloxone distribution, safe disposal, and harm reduction supply access, within the community health care setting. Health centers across the country that offer these services as part of comprehensive care shared their experiences and the ways that service expansion can contribute to engagement and care access.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.